- Home
- DVAX vs QQQX Comparison
DVAX vs QQQX Comparison
Compare DVAX & QQQX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- QQQX
- Stock Information
- Founded
- DVAX 1996
- QQQX 2007
- Country
- DVAX United States
- QQQX United States
- Employees
- DVAX N/A
- QQQX N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- QQQX Finance Companies
- Sector
- DVAX Health Care
- QQQX Finance
- Exchange
- DVAX Nasdaq
- QQQX Nasdaq
- Market Cap
- DVAX 1.3B
- QQQX 1.3B
- IPO Year
- DVAX 2004
- QQQX N/A
- Fundamental
- Price
- DVAX $10.26
- QQQX $27.01
- Analyst Decision
- DVAX Buy
- QQQX
- Analyst Count
- DVAX 4
- QQQX 0
- Target Price
- DVAX $26.50
- QQQX N/A
- AVG Volume (30 Days)
- DVAX 1.8M
- QQQX 127.6K
- Earning Date
- DVAX 08-07-2025
- QQQX 01-01-0001
- Dividend Yield
- DVAX N/A
- QQQX 7.03%
- EPS Growth
- DVAX N/A
- QQQX N/A
- EPS
- DVAX N/A
- QQQX N/A
- Revenue
- DVAX $316,268,000.00
- QQQX N/A
- Revenue This Year
- DVAX $23.23
- QQQX N/A
- Revenue Next Year
- DVAX $16.57
- QQQX N/A
- P/E Ratio
- DVAX N/A
- QQQX N/A
- Revenue Growth
- DVAX 26.66
- QQQX N/A
- 52 Week Low
- DVAX $9.22
- QQQX $20.27
- 52 Week High
- DVAX $14.63
- QQQX $25.99
- Technical
- Relative Strength Index (RSI)
- DVAX 42.08
- QQQX 59.53
- Support Level
- DVAX $10.27
- QQQX $26.12
- Resistance Level
- DVAX $11.45
- QQQX $26.90
- Average True Range (ATR)
- DVAX 0.45
- QQQX 0.24
- MACD
- DVAX -0.06
- QQQX -0.02
- Stochastic Oscillator
- DVAX 18.18
- QQQX 69.52
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About QQQX Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest
Nuveen NASDAQ 100 Dynamic Overwrite Fund is a closed-end management investment company. Its investment objective is to seek an attractive total return with less volatility than the Nasdaq 100 Index. Under normal circumstances, the Fund will invest at least 80% of its Assets in an equity portfolio made up of securities comprising the Nasdaq 100 Index (or securities that have economic characteristics that are similar to those securities comprising the Nasdaq 100 Index) that seeks to substantially replicate price movements of the Nasdaq 100 Index and is designed to support the Fund's option strategy.